NEW YORK — Lucira Health, a developer of an instrument-free, low-cost molecular diagnostics platform for infectious disease testing, filed for a $115 million initial public offering with the US Securities and Exchange Commission last week.
In the filing, the Emeryville, California-based company said it intends to float an undisclosed number of shares on the Nasdaq at a yet-to-be-determined price under the ticker symbol LHDX. BofA Securities, LifeSci Capital, and William Blair are underwriting the IPO.